Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Patients who admit to using buprenorphine by the intravenous route will be randomized to
either Subutex or Suboxone and be followed up for 3 months to determine if there is less
injection with Suboxone than with Subutex based primarily on patient diaries.
Patients randomized to Suboxone may continue to receive the product for a further 9 months at
their request and will be monitored at 3 month intervals.
Patients will receive a payment for the inconvenience of keeping a daily diary and to cover
their travel expenses.
Phase:
Phase 4
Details
Lead Sponsor:
Indivior Inc.
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone